Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
03 févr. 2021 07h00 HE
|
Sio Gene Therapies, Inc.
- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening, and enrollment in Stage 1 of the study...
Sio Gene Therapies to Sell Arvelle Stake as Part of Angelini Pharma’s Acquisition of Arvelle Therapeutics
04 janv. 2021 08h00 HE
|
Sio Gene Therapies, Inc.
Company to receive up to $20 million in upfront and milestone payments from non-dilutive transactionTransaction extends cash runway into 2022 NEW YORK, N.Y. and RESEARCH TRIANGLE PARK, N.C., Jan. ...
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
15 déc. 2020 16h01 HE
|
Sio Gene Therapies
- Generally well-tolerated with a favorable safety profile in five patients- Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6,...
Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis
02 déc. 2020 07h00 HE
|
Sio Gene Therapies
On-track to report topline results from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a...
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor
19 nov. 2020 08h00 HE
|
Sio Gene Therapies
A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapyDr. Gao recently served as President of the American Society for Gene and...
Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020
13 nov. 2020 07h00 HE
|
Sio Gene Therapies
Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseasesCompleted rebranding to Sio Gene Therapies as part of...
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
10 nov. 2020 07h00 HE
|
Axovant Gene Therapies
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicinesCompany’s common stock will trade on the NASDAQ...
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
09 nov. 2020 07h00 HE
|
Axovant Gene Therapies
AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseasesRepresents Axovant’s second IND clearance for a gene therapy program in the last 12...
Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020
29 oct. 2020 16h01 HE
|
Axovant Gene Therapies
Patient-level data in cohort 2 of SUNRISE-PD study demonstrates consistent, clinically meaningful outcomes and evidence of dose responseDelays in manufacturing process expected to postpone the start...
Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
22 oct. 2020 07h00 HE
|
Axovant Gene Therapies
Agenda to feature presentations from leading clinical researchers in Parkinson’s disease and the Michael J. Fox FoundationIndividual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to...